Mylan Can't Exclude Ex-CEO From EpiPen Antitrust Trial
A Kansas federal judge Wednesday rejected Mylan's bid to spare a former CEO from the late January trial in a massive antitrust class action accusing the drugmaker of unlawfully blocking generic...To view the full article, register now.
Already a subscriber? Click here to view full article